Damaged tissue

Damaged tissue is a physiological state characterized by the disruption of cellular structures and extracellular matrix integrity, often resulting from trauma, ischemia, or infection [Velnar et al., 2009]. It is not a specific molecular target but rather a complex pathological environment that releases Damage-Associated Molecular Patterns (DAMPs), such as HMGB1, which signal the need for an immune response [Roh & Sohn, 2018]. In the context of drug development, "damaged tissue" is considered an incorrect or overly broad target designation because therapeutic agents actually interact with specific proteins, such as growth factor receptors or inflammatory cytokines, to facilitate repair [NIH, 2022]. Clinical management of damaged tissue involves drugs like Becaplermin to stimulate cell proliferation or Collagenase for the removal of necrotic debris [StatPearls, 2023]. Monitoring the extent of damage is typically achieved through biomarkers like lactate dehydrogenase (LDH) and creatine kinase (CK), which leak into the circulation upon cell membrane rupture [StatPearls, 2023]. Consequently, while damaged tissue is the site of therapeutic action, it lacks the specificity required for a canonical molecular target.

Other names

Injured tissueLesionNecrotic tissueWoundTissue injury

Therapeutic strategies for damaged tissue involve the enzymatic debridement of necrotic material, the application of exogenous growth factors to stimulate cellular proliferation, and the use of antimicrobial agents to prevent infection [Velnar et al., 2009; StatPearls, 2023].